Clinical trials
Liver Transplant; Complications clinical trials
Below are recruiting liver transplant; complications clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06808945Recruiting
Prehabilitation program for liver transplant patients
This study tests a pre-surgery exercise and nutrition program (prehabilitation) for people waiting for a liver transplant. It aims to see if getting stronger before surgery can help you recover better after the transplant.
RotterdamAges 18 years+ - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT07053488RecruitingPhase 1/Phase 2
Gene-edited liver transplant to lower rejection risk
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Beijing, ChangpingAges 16–85 - NCT07169643RecruitingPhase 3
Darbepoetin trial for people waiting for a liver transplant
This trial tests if darbepoetin, a medicine that boosts red blood cells, can help people with anemia who are on the liver transplant waiting list. It may improve your strength and prepare you for surgery.
Barcelona, CataloniaAges 18–70 - NCT07269041RecruitingPhase 1/Phase 2
Immune tolerance after liver transplant
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Los Angeles, CaliforniaAges 18 years+ - NCT06774144Enrolling by invitationPhase 3
Rezafungin to prevent fungal infections in liver transplant patients
This trial tests whether a medicine called rezafungin can help prevent serious fungal infections in people who have received a liver transplant. If you have certain risk factors, this study may offer extra protection against infections.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06660095Enrolling by invitation
Measuring p50 during liver transplant surgery
This study is testing a new way to measure something called 'p50' during liver transplant surgery to see if it can help doctors better manage your care. It is for people who are having a planned liver transplant and are in relatively stable but serious health condition.
MalatyaAges 18–65 - NCT04246970Enrolling by invitation
Training program before and after liver transplant
This trial studies a structured exercise and training program before and after liver transplantation to help people recover better. You may be able to benefit if you’re getting an elective liver transplant and can safely participate in the training plan.
Valencia, ValenciaAges 18 years+ - NCT04234139Enrolling by invitation
Study of severe alcoholic hepatitis patients before early liver transplant
This study follows people with severe alcoholic hepatitis who are being considered for an early liver transplant before they’ve been sober for 6 months. It aims to better understand this group’s situation and ethics/safety as early transplantation plans are made.
Baltimore, MarylandAges 18 years+ - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT07530913Enrolling by invitation
Digital Rehabilitation Platform for Liver Transplant Patients
This study tests a smartphone or tablet-based exercise program designed to help people recovering from living donor liver transplant surgery. The goal is to see if using guided exercises on a digital device at home improves recovery and quality of life after transplant.
SeoulAges 20–65 - NCT05285878Enrolling by invitationPhase 2
Fingolimod to protect kidney function after kidney transplant
This trial tests whether fingolimod can reduce kidney scarring and preserve kidney function after a new kidney transplant. It focuses on people who are in the early period after transplant who may be at risk for scarring in the kidney.
Houston, TexasAges 18–65 - NCT05146336Recruiting
CytoSorb registry for critically ill patients needing blood treatment
This registry collects information about critically ill patients who receive the CytoSorb 300 mL blood treatment. It may help doctors better understand when the treatment works best and when it should not be used.
KlagenfurtAges Any age - NCT05195944Enrolling by invitationPhase 4
Semaglutide versus sitagliptin after liver transplant for diabetes
This trial compares two diabetes medicines—semaglutide and sitagliptin—in people who have had a liver transplant and have type 2 diabetes (or diabetes after transplant). It’s looking to see which medicine works better and is safe for blood sugar control in the transplant setting.
Toronto, OntarioAges 18 years+ - NCT06254248RecruitingPhase 2
Safety of two cancer drugs after liver transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) for people whose liver cancer has returned after a liver transplant and cannot be treated with surgery or other local procedures. The goal is to see if this treatment is safe for liver transplant recipients.
ClichyAges 18–90 - NCT05170971Recruiting
Fecal transplant trial for worsening liver failure
This trial studies fecal microbiota transplantation (a transfer of healthy gut bacteria from a donor) to help people with worsening liver failure. It may help by changing gut bacteria, which can affect complications like confusion, fluid buildup, infections, and kidney problems.
Ningbo, ZhejiangAges 18–65 - NCT07247877Enrolling by invitation
Study of small liver grafts for portal hypertension treatment
This trial explores using smaller liver grafts in a partial transplant to treat portal hypertension, which may help patients avoid full transplant risks. It compares this approach to standard liver transplant.
Ages 14 years+ - NCT05327478Recruiting
Compare treatments for controlled donation after circulatory death
This trial compares different care approaches for adult donors in a specific type of controlled donation after the heart stops. It aims to find which approach best supports organ/tissue use after donation.
Rotterdam, South HollandAges 50–75 - NCT07028112Recruiting
Iron and liver health after stem cell transplant
This study looks at how too much iron in the body (from past transfusions) affects the liver in people who had a stem cell transplant at least 10 years ago. It will help doctors understand who needs special monitoring for liver problems.
ParisAges 18 years+ - NCT06346665Recruiting
Transplant infection study for organ and stem cell recipients
This trial follows people who have had a recent organ or stem cell transplant to learn more about infections and how they can be prevented. You may be asked to provide samples and information over time.
MünchenAges Any age - NCT02081755Enrolling by invitationPhase 4
Everolimus after liver transplant to lower liver cancer return
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
San Francisco, CaliforniaAges 18 years+ - NCT05679024RecruitingPhase 3
Apixaban to prevent stroke in atrial fibrillation and kidney failure
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
HelsinkiAges 18 years+ - NCT05702931RecruitingPhase 4
Semaglutide for high blood sugar after kidney transplant
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
CopenhagenAges 18–80
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver transplant; complications?
- Yes. Clin2 currently lists 63 recruiting liver transplant; complications studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver transplant; complications trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver transplant; complications trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.